Aust Ctr for Blood Diseases

    Research areas

  • Haematology, biomarkers of drug responsiveness, blood cancer, bortezomib, clinical research, drug resistance, ell surface phosphatase CD45, haematological malignancies, mouse model, multiple myeloma, translational research, novel therapeutics, epigenetic therapy


Professor Andrew Spencer is Head of the Malignant Haematology and Stem Cell Transplantation Service at The Alfred Hospital, Melbourne; Professor of Haematology, Monash University; and, Head of the Myeloma Research Group at the Australian Centre for Blood Diseases, Melbourne.

Andrew Spencer completed his medical training in clinical and laboratory haematology in 1992. Subsequently, he was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, where he undertook research into B-cell clonality in chronic myeloid Leukaemia under the supervision of Professors John Goldman and Junia Melo and was awarded a Doctorate of Medicine from the University of London. Andrew moved to The Alfred Hospital in 1999 where he established an independent translational research program. In parallel he established a first-in-human and early phase haematology clinical research unit at The Alfred and was appointed Head of the Malignant Haematology and Stem Cell Transplantation Services in 2007.

Professor Spencer has secured research funding of more than $12 million via funding bodies, industry collaborations and philanthropy. He has > 100 peer reviewed publications with citations in excess of 3300. Andrew serves on the scientific advisory boards of the International Myeloma Foundation (IMF), International Myeloma Working Group (IMWG) and the European Myeloma Network (EMN). He is a Director of the Australasian Leukaemia and Lymphoma Group (ALLG) and the International Myeloma Society (IMS). He is the immediate past-President of the Haematology Society of Australia and New Zealand (HSANZ).

Research interests

The research program of Professor Andrew Spencer aims to:

(1) identify more effective and rationale novel therapeutic strategies for MM through the identification of drug resistance processes and/or biomarkers of drug responsiveness (employing transcriptional and proteomic studies in mouse models and primary tumours) with rapid translational of synergistic drug combinations into early phase investigator-initiated clinical trials, and

(2) identify mechanisms of MM disease progression, with a particular focus on the role of the cell surface phosphatase CD45, and

(3) explore the role of different modalities of minimal residual disease (MRD) detection in MM to optimise their utility in clinical practice.

ID: 846062